Table 1.
Characteristics of lung transplant patients.
| All | Stable | Infection | CLAD | p | |
|---|---|---|---|---|---|
| n = 20 | n = 6 | n = 5 | n = 9 | ||
| Age, median (IQR) | 55 (32–60) | 51.5 (20–60) | 58 (36–62) | 54 (39–57) | 0.65 |
| Gender: Male, n (%) | 9 (42.9) | 2 (33.3) | 2 (40.0) | 4 (44.4) | 0.17 |
| Diagnosis, n (%) | |||||
| COPD | 10 (50.0) | 3 (50.0) | 3 (60.0) | 4 (44.4) | 0.86 |
| ILD | 2 (10.0) | 0 (0.0) | 0 (0.0) | 2 (22.2) | 0.47 |
| CF | 5 (25.0) | 2 (33.3) | 1 (20.0) | 2 (22.2) | 1.00 |
| Other | 3 (15.0) | 1 (16.7) | 1 (20.0) | 1 (11.1) | 1.00 |
| Immunosupressive treatment, n (%) | |||||
| CsA+AZA+P | 2 (10.0) | 1 (16.7) | 0 (0.0) | 1 (11.1) | 1.00 |
| CsA+MMF+P | 2 (10.0) | 0 (0.0) | 2 (40.0) | 0(0.0) | 0.05 |
| CsA+P | 1 (5.0) | 0 (0.0) | 1 (20.0) | 0 (0.0) | 0.25 |
| FK+AZA+P | 5 (25.0) | 1 (16.7) | 1 (20.0) | 3 (33.3) | 0.82 |
| FK+MMF+P | 5 (25.0) | 3 (50.0) | 1 (20.0) | 1 (11.1) | 0.35 |
| FK+P | 4 (20.0) | 1 (16.7) | 0 (0.0) | 3 (33.3) | 0.41 |
| FK | 1 (5.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) | 1.00 |
| Type of LTx | |||||
| SSLT | 18 (90.0) | 6 (100.0) | 5 (100.0) | 7 (77.8) | 0.48 |
| SLT | 2 (10.0) | 0 (0.0) | 0 (0.0) | 2 (22.2) | |
| Survival post LTx (years), median (IQR) | 7.0 (4.1–9.7) | 5.6 (3.8–8.7) | 4.3 (3.0–7.4) | 7.5 (5.9–11.9) | 0.18 |
| Sampling time post LTx (months), median (IQR) | 3.9 (0.9–6.6) | 1.9 (0.7–5.1) | 0.9 (0.5–4.7) | 6.6 (4.8–9.3) | 0.02 |
IQR, interquartile range; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; CF, cystic fibrosis; CsA, Cyclosporine; FK, Tacrolimus; P, Prednisolone; LTx, Lung Transplantation.